Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Camurati-Engelmann Syndrome 1

Interventions

pembrolizumab 1273Specimen Handling 871Carboplatin 832Magnetic Resonance Spectroscopy 808Cyclophosphamide 803Cisplatin 729Nivolumab 659Paclitaxel 631Radiotherapy 574Gemcitabine 572Biopsy 529Bevacizumab 476Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 358Fluorouracil 355atezolizumab 344durvalumab 334Rituximab 333Doxorubicin 317Radiosurgery 309Pemetrexed 306Drug Therapy 303Ipilimumab 294Standard of Care 293Etoposide 285Radiation 281

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × LY3300054 × 1 year × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡